MA26998A1 - Conjugues peg de hgt-nk4 - Google Patents

Conjugues peg de hgt-nk4

Info

Publication number
MA26998A1
MA26998A1 MA27285A MA27285A MA26998A1 MA 26998 A1 MA26998 A1 MA 26998A1 MA 27285 A MA27285 A MA 27285A MA 27285 A MA27285 A MA 27285A MA 26998 A1 MA26998 A1 MA 26998A1
Authority
MA
Morocco
Prior art keywords
hgt
peg conjugates
conjugates
peg
Prior art date
Application number
MA27285A
Other languages
English (en)
Inventor
Michael Brandt
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26998A1 publication Critical patent/MA26998A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA27285A 2001-02-23 2003-08-19 Conjugues peg de hgt-nk4 MA26998A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (fr) 2001-02-23 2001-02-23 Conjugués du PEG et du HGF-NK4

Publications (1)

Publication Number Publication Date
MA26998A1 true MA26998A1 (fr) 2004-12-20

Family

ID=8176596

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27285A MA26998A1 (fr) 2001-02-23 2003-08-19 Conjugues peg de hgt-nk4

Country Status (27)

Country Link
US (2) US20030012775A1 (fr)
EP (2) EP1234583A1 (fr)
JP (2) JP2004521139A (fr)
KR (2) KR20030072629A (fr)
CN (1) CN100339393C (fr)
AR (1) AR032574A1 (fr)
AU (1) AU2002233354B2 (fr)
BG (1) BG108125A (fr)
BR (1) BR0207510A (fr)
CA (1) CA2438308A1 (fr)
CZ (1) CZ20032511A3 (fr)
EC (1) ECSP034741A (fr)
GT (1) GT200200038A (fr)
HR (1) HRP20030659A2 (fr)
HU (1) HUP0400979A2 (fr)
IL (1) IL157426A0 (fr)
MA (1) MA26998A1 (fr)
MX (1) MXPA03007130A (fr)
NO (1) NO20033737L (fr)
PA (1) PA8540501A1 (fr)
PE (1) PE20020992A1 (fr)
PL (1) PL367402A1 (fr)
RU (1) RU2293574C2 (fr)
SK (1) SK11652003A3 (fr)
WO (1) WO2002074344A2 (fr)
YU (1) YU65103A (fr)
ZA (1) ZA200306080B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019991A2 (fr) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Antagoniste nk4 du facteur de croissance de l'hepatocyte/du facteur de dispersion pour le traitement de gliome
WO2004085471A2 (fr) * 2003-03-24 2004-10-07 Novo Nordisk A/S Derives de glp-2
DE602005003929T2 (de) 2004-03-03 2008-12-04 F. Hoffmann-La Roche Ag Verfahren zur aufreinigung eines n-terminalen fragments des hepatozytenwachstumsfaktors
CN1926236A (zh) * 2004-03-03 2007-03-07 霍夫曼-拉罗奇有限公司 肝细胞生长因子的n－端片段的重组表达的方法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
KR101290322B1 (ko) * 2008-04-09 2013-07-26 주식회사 바이로메드 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
JP2016528879A (ja) 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
HK1226308A1 (zh) 2013-08-30 2017-09-29 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
KR20170068553A (ko) 2014-10-14 2017-06-19 아르모 바이오사이언시스 인코포레이티드 인터류킨-15 조성물 및 이의 용도
JP6675394B2 (ja) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
WO2020158690A1 (fr) * 2019-01-28 2020-08-06 東レ株式会社 Forme modifiée par du polyéthylène glycol d'un facteur de croissance des hépatocytes ou d'un fragment actif de celui-ci
US20220220176A1 (en) * 2019-01-28 2022-07-14 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023541A1 (fr) 1992-05-18 1993-11-25 Genentech, Inc. Variantes du facteur de croissance des hepatocytes
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
DE69503849T2 (de) * 1994-03-31 1999-04-01 Amgen Inc., Thousand Oaks, Calif. Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten
RU2158603C2 (ru) * 1994-05-31 2000-11-10 Амген Инк. Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
ATE257844T1 (de) * 1995-03-10 2004-01-15 Nakamura Toshikazu Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
CN1168495C (zh) * 1997-01-15 2004-09-29 凤凰药理学公司 被修饰的肿瘤坏死因子
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (fr) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site
TR200101751T2 (tr) * 1998-04-28 2002-05-21 Applied Research Systems Ars Holding N.V. Poliol-IFN-beta konjugatları
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
CA2431964C (fr) * 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugues d'erythropoietine (pep) et de polyethylene glycol (peg)

Also Published As

Publication number Publication date
BG108125A (bg) 2004-09-30
CN100339393C (zh) 2007-09-26
SK11652003A3 (sk) 2004-05-04
PE20020992A1 (es) 2002-11-01
CA2438308A1 (fr) 2002-09-26
YU65103A (sh) 2006-03-03
JP2004521139A (ja) 2004-07-15
IL157426A0 (en) 2004-03-28
WO2002074344A2 (fr) 2002-09-26
PL367402A1 (en) 2005-02-21
KR20030072629A (ko) 2003-09-15
ECSP034741A (es) 2003-10-28
EP1389132A2 (fr) 2004-02-18
US20030012775A1 (en) 2003-01-16
JP2010174034A (ja) 2010-08-12
ZA200306080B (en) 2004-11-23
NO20033737L (no) 2003-10-21
WO2002074344A3 (fr) 2003-12-04
CZ20032511A3 (en) 2004-03-17
AR032574A1 (es) 2003-11-12
RU2003127395A (ru) 2005-03-20
US7846896B2 (en) 2010-12-07
US20080085857A1 (en) 2008-04-10
BR0207510A (pt) 2004-07-27
KR20090020713A (ko) 2009-02-26
AU2002233354B2 (en) 2006-11-30
HRP20030659A2 (en) 2004-08-31
HUP0400979A2 (hu) 2004-08-30
NO20033737D0 (no) 2003-08-22
GT200200038A (es) 2002-09-30
MXPA03007130A (es) 2003-11-18
CN1571679A (zh) 2005-01-26
PA8540501A1 (es) 2002-09-30
RU2293574C2 (ru) 2007-02-20
EP1234583A1 (fr) 2002-08-28

Similar Documents

Publication Publication Date Title
FR17C1054I2 (fr) Conjugues de type vecteur-derive de calicheamicine
NO20034774L (no) Melanokortinreseptorligander
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE50103741D1 (de) Welle-Nabe-Verbindung
NO20033059L (no) Silrörsdeksel
ATE335486T1 (de) Hydrazono-malonitrile
NO20033737D0 (no) PEG-konjugater av IIGT-NK4
DE50208298D1 (de) Durchbiegungseinstellwalze
PT1268453E (pt) Metabolitos de agonista/antagonista de estrogenio
DE50203412D1 (de) Schwenkkolbenverdränger
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
ATE355059T1 (de) Isoxazolopyridinone
DE50201862D1 (de) Messwandler
DE50207767D1 (de) Durchbiegungseinstellwalze
PT1317179E (pt) Formulacoes de mesotriona
DE50212401D1 (de) Durchbiegungseinstellwalze
DE50203093D1 (de) Losradlager
ATA18372001A (de) Gelenksbolzenbaueinheit
DE60143209D1 (de) Zweiport-demodulationseinrichtung
NO20035742D0 (no) Kjemisk modifisert progenipoietin konjugater
ATE319694T1 (de) Phenylalkyne
DE50202088D1 (de) Garmodulsystem
ATA13992002A (de) Schlackengranulierungsanlage
DE60229395D1 (de) Altung
DE50108381D1 (de) Synchronisierschaltungsanordnung